LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

Recurrent or metastatic cervical cancer (r/mCC) is a global medical problem with few effective treatments, especially in the second- or third-line settings where available therapies have very limited activity. The phase 2 study innovaTV 204 was conducted to assess the potential of tisotumab vedotin, a tissue factor–directed antibody–drug conjugate, to address this high unmet need in patients with r/mCC. Patients with r/mCC with disease...